
|Videos|May 7, 2021
Dr. Alexander Kretschmer explains how the ExoDx Prostate test works
Author(s)Urology Times staff
The risk assessment tool helps determine whether a prostate biopsy is necessary when PSA screening is ambiguous.
Advertisement
Dr. Alexander Kretschmer, MD, discusses the clinical interpretation and value of the ExoDx Prostate test (EPI test). The non-invasive, urine-based genomic test is a risk assessment tool that helps physicians and patients determine whether a prostate biopsy is necessary when PSA screening provides an ambiguous result.
Kretschmer is an assistant professor of Urology at Ludwig-Maximilians-University Munich.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Daniel Spratt, MD, on using ArteraAI to guide salvage therapy decisions
2
FDA updates in urology: December 2025
3
Top 10 Urology Times bladder cancer articles of 2025
4
The UroOnc Minute: En bloc resection vs TURBT, with Jeremy Y.C. Teoh, MBBS, FRCSEd, FCSHK, FHKAM
5



















